Hikma Hit By Approval Delays, But Advair Diskus Generic Expected Next Year
Executive Summary
Jordan's Hikma claims to be a more balanced generics company after the Roxane acquisition, and expects 2017 approval of an Advair Diskus generic, but delays in US generic approvals held back profits in the 2016 first half.